

**The Role of Procalcitonin in Diagnosis of
Bacterial Infection in Hepatocellular Carcinoma
Patients After Trans Arterial
Chemoembolization**

Thesis

*Submitted for Partial Fulfillment of Master Degree
in Tropical Medicine by*

Moataz Ahmed Hassan

MBBCH--

Faculty of Medicine - Ain Shams University

Supervised by

Prof. Hesham Khalil Dabbous

Professor of Tropical Medicine

Faculty of Medicine - Ain Shams University

Dr. Fatma Ahmed Ali El-din

Assistant Professor of Tropical Medicine

Faculty of Medicine - Ain Shams University

Dr. Iman Mohammed Fawzy Montasser

Lecturer of Tropical Medicine

Faculty of Medicine - Ain Shams University

Faculty of Medicine

Ain Shams University

2013

List of Abbreviations (Cont.)

Abbrev.	Full term
PVE	Portal vein embolization
RCTs.....	Randomized controlled trial study
RFA	Radiofrequency ablation
RFTA.....	Radifrequency thermal ablation
RILD.....	Radiation induced liver disease
RT-PCR.....	Reverse-transcriptase polymerase chain reaction
SCCA	Squamous cell carcinoma antigen
SHARP	Sorafenip HCC Assessment Randomized protocol
ShRNA	Short hairpin RNA
SiRNA	Small interfering RNA
SIRT	Selective internal radiation therapy
TA-4	Tumor associated antigen
TAC.....	Transarterial Chemotherapy
TACE	Transarterial Chemoembolization
TAE	Transarterial embolization
TARE	Transarterial radioembolization
TGF	Transforming growth factor
TGF-B1	Transforming growth factor B1
TLS.....	Tumor lysis syndrome
TNM staging.....	Tumor node metastasis staging
UICC	Union International Centre de Cancer
VEGF	Vascular endothelial growth factor PEI Percutaneous ethanol injection
PEIT	Percutaneous ethanol injection treatment
PI3K	Phosphoinositide 3-kinase
PIVKAI	Prothrombin induced by vitamin K absence II
PLAT.....	Percutaneous Laser ablation Thermotherapy
PMCT	Percutaneous microwave thermotherapy
PUO.....	Pyrexia of unknown origin
PVA	Polyvenyle alcohol HS-AFP Hepatoma specific Alpha fetoprotein
HSPS	Heat shock protein
HSV-tk	Herpes simplex virus thymidine kinase
hTERT	Human telomerase reverse transcriptase
ICG	Indocyanine green
Ics	Immune complexes
IFN	Interferon
IGF	Insulin-like growth factor
IGF-2	Insulin growth factor-II



*First of all, I praise **Allah** almighty for helping me to proceed and to complete this work.*

*It is of my pleasure to express my grateful respect and gratitude to **Prof. Hesham Kalil Dabbous** Professor of Tropical Medicine Ain Shams University hospitals, who suggested the subject, for his grateful help, supervision, guidance and moral support throughout the work.*

*I'd like to express my deep appreciation and profound gratitude to **Assistant Prof. Fatma Ahmed Ali El-Din** Assistant Professor of Tropical Medicine, Faculty of Medicine, Ain Shams University, for her effective guidance, valuable suggestions and unlimited help throughout the work as well.*

*And also special thanks to **Dr. Iman Mohamed Fawzi** Lecturer of Tropical Medicine, Faculty of Medicine, Ain Shams University, for her effective guidance, valuable suggestions and unlimited help throughout the work as well.*

I would also like to mention my thanks and gratitude to my family, my wife.

Moataz Ahmed Hasan

List of Contents

Title	Page No.
Introduction	1-3
Aim of the work	4
Review of literature	
Chapter (1): Hepatocellular carcinoma	5-62
Chapter (2): Procalcitonin	63-89
Subjects and Methods	90-95
Results.....	96-107
Discussion	108-116
Conclusions & Recommendations	117
Summary	118-121
References	122-177
Arabic summary	---

List of Tables

Table No.	Title	Page
Table (1):	Okuda Staging Variables	28
Table (2):	Child-Pugh Score:.....	29
Table (3):	Cancer of liver Italian Program (CLIP) scoring system for HCC	30
Table (4):	Treatment modalities of HCC	33
Table (5):	Several methods of locoregional treatment of HCC.....	37
Table (6):	Descriptive statistics of the personal history in the studied cases	96
Table (7):	Clinical data at the initial presentation in the studied cases:	97
Table (8):	Post interventiona clinical data in the studied cases:	98
Table (9):	Comparison between pre & post intervention as regards clinical status including (ascites&Child) in the studied cases:.....	99
Table (10):	Radiological data of the hepatic focal lesionin the studied cases	100
Table (11):	Comparison between pre & post interventional laboratory results:	101
Table (12):	Blood cultere results of the studeid patients	102
Table(13):	Correlation between post intervention procalcitonin and (demographics & lab. data).....	103
Table (14):	Correlation between post interventional CRP,(demographics & laboratory results) in the studied cases:	104
Table (15):	Shows comparison between patients' results with positive & negative culture in the studiedcases:.....	105

List of Figure

Figure No.	Title	Page
Figure (1):	Multiphasic axial CT scans show hypervascular HCC poorly enhancing in early arterial phase (A), but best in late arterial phase (B)	23
Figure (2):	Dynamic MRI images showing small HCC focal lesion with enhancement in arterial phase (a) with wash out in delayed phase (b)	24
Figure (3):	Algorithmic diagnosis of HCC	26
Figure (4):	Diagnostic algorithm and recall policy figure 4:One imaging technique only recommended in centers of excellence with high-end radiological equipment. HCC radiological hallmark: arterial hypervascularity and venous/late phase washout	27
Figure (5):	BCLC staging and treatment schedule	31
Figure (6):	(a) Contrast-enhanced CT scan performed before ethanol injection shows high-attenuation area in posterior superior segment. (b) Contrast-enhanced helical CT scan performed after four sessions of percutaneous ethanol injection therapy shows necrotic area that is larger than viable area depicted on CT before treatment	39
Figure (7):	Successful TACE of HCC. (a) Contrast-enhanced MDCT shows a large encapsulated HCC, which is hypervascular in the arterial phase. There is also a smaller lesion in segment 4 present. (b) After successful chemo-embolisation of the large tumor, unenhanced CT demonstrate lipiodol in the tumor bed. There are also gas bubbles present due to tumor necrosis. The smaller lesion in segment 4 is not treated	52

List of Figure (Cont.)

Figure No.	Title	Page
Figure (8):	Schematic diagram of CALC I expression in adipocytes and thyroidal C cells	63
Figure (9):	Components and calculation of Mortality in Emergency Department Sepsis (<i>MEDS</i>) score as originally described.....	75
Figure (10):	The importance of the procalcitonin (PCT) assay used. The cut-offs for antibiotic use in respiratory tract infections (RTI) were validated in intervention trials. Importantly, these cut-off ranges are dependent on the clinical context and have to be adapted accordingly (eg lower cut-off ranges with markedly impaired pulmonary reserve, higher cut-off ranges in patients with systemic inflammatory response syndrome on an intensive care unit)	83
Figure (11):	Shows Receiver Operating Characteristic (ROC) curve analysis showing the diagnostic performance of CRP. Area under the curve was 0.64.cut off value was 17mg/ml with sensitivity 60% & specificity 56.8%.	106
Figure (12):	Shows Receiver Operating Characteristic (ROC) curve analysis showing the diagnostic performance of procalcitonin. Area under the curve was 0.98 cut of value was 0.95ng/ml with sensitivity 80% & specificity 97.3%.	107

List of Abbreviations

Abbrev.	Full term
⁹⁰ Y	Yatrium 90
AASLD.....	American association for study of liver disease
AFP.....	Alpha fetoprotein
AFU.....	Alpha L-Fucosidase
BCLC staging.....	Barcelona Clinic Liver Cancer staging
BMSC.....	Bone marrow mononuclear stem cell
CCC.....	Cholangiocarcinoma
CD	Cytosine deaminase
CEA	Carcinoembryonic antigen
CLD.....	Chronic liver Disease
CLIP staging.....	Cancer of liver Italian program staging
CLIP	Cancer liver Italian program
CT.....	Computed Tomography
CTA.....	CT arteriography
CTAP.....	CT arteriportography
DCP	Des-gama-carboxy prothrombin
dsRNA.....	Double stranded RNA
DUS.....	Doppler Ultrasound
ECLIA	Electrochilu-minescence immunoassay
EGF	Epidermal growth factor
EPA	Environmental protection Agency
ERK.....	Extracellular signal-regulated kinase
EUS	Endoscopic ultrasonography
FNH.....	Focal nodular hyperplasia
FUDR	Fluorodeoxyuridine
GCV	Ganciclovir
GGT.....	Gama glutamyl transferase
GPC3	Glypican-3
GRE.....	Gradient recall echo
HBV	Hepatitis B virus
HCC.....	Hepatocellular carcinoma
HCV	Hepatitis C virus
HDV	Hepatitis D virus
HIFU.....	High intensity focus ultrasound

List of Abbreviations (Cont.)

Abbrev.	Full term
IL-8.....	Interleukin-8
ILA	interstitial laser ablation
ILP	Interstitial laser Photocoagulation
IOUS.....	Intra-operative ultrasonography
LA.....	Laser ablation
LAK cells	Lymphokine activated killer cells
LC-705	Lactobacillus rhamnosus
LCA	Lens culinaris agglutinin
LDH.....	Lactat dehydrogenase
LDLT.....	Living donor liver transplantation
LITT	Laser induced thermotherapy
LT	Liver Transplantation
L-TAC	Transarterial chemotherapy, lipiodolization TAC+E: Transarterial chemotherapy and particle embolization
L-TAC+E	Transarterial chemotherapy, lipiodolization and particle embolization
MAGE-1	Melanoma antigen gene
MAPK	Mitomycin-activated protein kinase
mCRC.....	Metastatic colorectal Cancer
MDCT	Multi-detector CT
MELD.....	Model for end stage liver disease
MOVC.....	Membranous obstruction of inferior vena cava
mRNA	microRNA
MSCT	Multi-slice CT
mTOR.....	Mammalian target of rapamycin
MWA.....	Microwave ablation
NAFLD.....	Non alcoholic liver disease
NRH	Nodular regenerative hyperplasia
NSAIDS	Nonsteroidal anti-inflammatory drugs
OLT	Orthotopic liver transplantation
OS	Overall survival
P CEA.....	Polyclonal carcino-embryonic antigen
P53.....	Tumour suppressor gene
PAAI or PAI.....	Percutaneous acetic acid Injection
PDGF.....	Platelet-derived growth factor

INTRODUCTION

Procalcitonin (PCT), the precursor of the hormone calcitonin, is produced under normal conditions in the C cells of the thyroid gland. In healthy subjects, PCT levels are <0.10 ng/ml. PCT determination was first performed in 1993 in children to differentiate bacterial from viral meningitis (*Assicot et al., 1993*).

Since that date, PCT has become a marker of bacterial infection and there is a widening range of indications for its use (*Ferriere, 2000 & Schwarz et al., 2000*).

Procalcitonin is a 116 amino acid peptide with a sequence identical to that of the prohormone of calcitonin (*Le Moullec et al., 1984*). But PCT itself has no known hormonal activity. Under normal metabolic conditions, PCT is only present in the C cell of the thyroid gland. In bacterial infection and sepsis its level increase in the serum; however, intact PCT is found in the blood and, more importantly, its level is related to the severity of sepsis (*De Werra et al., 1997 & Ugarte et al., 1999*).

The origin of inflammatory synthesis of PCT has not been clarified yet, neuroendocrine cells of different organs (lung, intestine, kidney, pancreas, adrenal gland, and more recently the liver) have been proposed as a major source of PCT production (*Morgenthaler et al., 2003*).

Determination of the PCT level is now routinely performed in intensive care and surgery units to provide rapid evidence of bacterial origin of a shock or a respiratory distress syndrome; to differentiate pancreatitis with infected necrosis more easily from non-complicated pancreatitis; and for early detection of infectious postoperative complications (*De Werra et al., 1997 & Reith et al., 1998*).

Several meta-analyses concluded that in critically ill patients, PCT is superior to C-reactive protein (CRP) for diagnosing bacterial infections (Lim et al., 2003). PCT has been proposed as a marker of bacterial infection in critically ill patients (*Ugarte et al., 1999 & Muller et al., 2000*).

Post-ablation and Embolization Syndrome

This syndrome is a transient self limiting symptom or sign complex of low-grade fever and general malaise (*Lee et al., 1997*). The duration depends on the volume of necrosis produced and the overall condition of the patient. If small areas are treated, the patient is unlikely to experience post-ablation syndrome at all. If very large areas of liver tumors are ablated, the syndrome may persist for 2 to 3 weeks. The majority of patients who have this syndrome will experience some malaise for 2 to 7 days depending on the volume of tumor and surrounding tissue ablated and the integrity of the patient's immune system (i.e. patients being treated with steroids or those who have small tumors may experience post ablation syndrome) (*Chopra , 2000*).

The procedure is generally well tolerated, with major complications in only 4-7% of procedures and a 30-day mortality of approximately 1% (Sakamoto et al., 1998). However, the procedure has been associated with several complications such as acute hepatic failure (2.6% of cases), liver infarction (0.3%), hepatic biloma formation (0.8%), liver abscess (0-1.4%), or septicemia (2.6-11%) (*Chung et al., 1996*). A standard antibiotic regimen with cephalosporin and levofloxacin has been used for prophylaxis against such post-procedural infectious complications (*Geschwind et al., 2002*).

AIM OF THE WORK

To study the value of serum procalcitonin in diagnosis of bacterial infection in hepatocellular carcinoma patients after Trans arterial chemoembolization.

HEPATOCELLULAR CARCINOMA

Hepatocellular carcinoma (HCC) is the fifth most common malignant tumor worldwide, with an increasing global annual incidence (*Hussain et al., 2008*).

Hepatocellular carcinoma (HCC) is generally occurring in association with cirrhosis, particularly due to hepatitis C, hepatitis B, alcohol, hereditary hemochromatosis, and primary biliary cirrhosis (*Bruix and Sherman, 2005*). There is a continuously increasing trend of HCC in Egypt (*Shaker et al., 2011*). Liver cancer is the sixth most common cancer (749,000 new cases), the third cause of cancer related death (692,000 cases), and accounts for 7% of all cancers HCC represents more than 90% of primary liver cancers and is a major global health problem (*European association of study of liver disease (EASL), 2012*).

El-Zayadi et al. (2001) reported that, in Egypt, 4.7% of chronic liver disease patients suffer from HCC. The development of HCC is mainly due to high rates of hepatitis B and C infections among Egyptian patients. In 2005 the authors reported increase of HCC among chronic liver disease patients up to 7.2% (*El-Zayadi et al., 2005*).

The risk of developing of HCC for a patient with HCV-related cirrhosis is approximately 2-6% per year (*Sangiovanni et al., 2004*). But it usually develops in an already damaged, often cirrhotic liver (*Masuzaki and Omata, 2008*). So screening should be applied to those patients (*Ryder, 2003a*). While

Patients with chronic hepatitis B virus infection are known to be at risk for HCC even without cirrhosis, so all patients with chronic HBV (those who are HBsAg +ve) should be considered for screening for HCC (*Lok & McMahon, 2001*).

The incidence of HCC generally increases with age, although there are geographic differences. The majority of patients are 40–60 years old with a peak incidence in the eighth decade (*Goodman, 2007*).

HCC is a multi-stage disease whose occurrence is linked to environmental and life style factors. The great variations in levels of carcinogenic factors in the environment account for the different incidences of the tumor (*Ikai et al., 2004*).

Regardless of geographic location, HCC occurs more frequently in men than women, with (male to female) ratios in various countries ranging from (2:1 to 5:1) (*Goodman, 2007*).

This malignancy is becoming recognized as an early complication and the most frequent cause of death in persons with viral-associated cirrhosis (*Benvegnù et al., 2004*).

Optimal care of the patient with HCC is best achieved through referral to a multidisciplinary team of hepatologists, transplant and hepatobiliary surgeons, interventional radiologists, and oncologists. The therapeutic plan should follow **EASL 2012** practice guidelines for the management of HCC, taking into consideration the different treatment modalities, including resection, liver transplantation, local ablative therapies, and chemotherapy (*EASL, 2012*).